L Aarden
Overview
Explore the profile of L Aarden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamnitski A, Krieckaert C, Nurmohamed M, Hart M, Dijkmans B, Aarden L, et al.
Ann Rheum Dis
. 2011 Sep;
71(1):88-91.
PMID: 21914626
Objective: To investigate the relationship between serum etanercept levels and clinical response. Methods: In 292 etanercept-treated patients with rheumatoid arthritis clinical and pharmacological data were determined at baseline and after...
2.
Tran L, Baars J, Aarden L, Beijnen J, Huitema A
Hum Antibodies
. 2010 Jun;
19(1):7-13.
PMID: 20555126
Background: In this study, we investigated the pharmacokinetics of rituximab in patients with CD20 positive non-Hodgkin lymphoma, to get more insight into the factors that influence the pharmacokinetics of rituximab....
3.
Thurlings R, Teng O, Vos K, Gerlag D, Aarden L, Stapel S, et al.
Ann Rheum Dis
. 2009 Jul;
69(2):409-12.
PMID: 19596693
Objectives: To analyse whether persistence of synovial B lineage cells and lack of clinical response to rituximab treatment in patients with rheumatoid arthritis (RA) are associated with low rituximab serum...
4.
Bartelds G, Wijbrandts C, Nurmohamed M, Stapel S, Lems W, Aarden L, et al.
Ann Rheum Dis
. 2009 Jul;
69(5):817-21.
PMID: 19581278
Objective: To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in rheumatoid arthritis (RA). Methods: This cohort study consisted of 235...
5.
Bos W, Bartelds G, Vis M, van der Horst A, Wolbink G, van de Stadt R, et al.
Ann Rheum Dis
. 2008 May;
68(4):558-63.
PMID: 18445623
Objective: To investigate the dynamics of IgG1 and IgG4 anti-citrullinated protein antibody (ACPA) subclasses during anti-tumour necrosis factor (TNF) treatment in patients with rheumatoid arthritis (RA). Methods: IgG, IgG1 and...
6.
Bartelds G, Wolbink G, Stapel S, Aarden L, Lems W, Dijkmans B, et al.
Ann Rheum Dis
. 2006 Aug;
65(9):1249-50.
PMID: 16905585
No abstract available.
7.
Aarden L
Scand J Immunol
. 2005 Jun;
62 Suppl 1:33-5.
PMID: 15953181
Abstract In the mid-1970s, Ivan Lefkovits and co-workers introduced limiting dilution analysis of T and B cells as a method to quantify antigen-specific T and B cells. In this study,...
8.
Nielen M, van der Horst A, van Schaardenburg D, van der Horst-Bruinsma I, van de Stadt R, Aarden L, et al.
Ann Rheum Dis
. 2005 Jan;
64(8):1199-204.
PMID: 15640269
Background: The anti-cyclic citrullinated peptide (CCP) test has a high sensitivity and specificity for rheumatoid arthritis, although CCP is not the physiological target of the autoantibodies. Citrullinated fibrin is abundant...
9.
Wolbink G, Voskuyl A, Lems W, de Groot E, Nurmohamed M, Tak P, et al.
Ann Rheum Dis
. 2004 Oct;
64(5):704-7.
PMID: 15485995
Objective: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA). Methods: Disease activity and serum trough infliximab levels...
10.
Naldini A, Aarden L, Pucci A, Bernini C, Carraro F
Br J Pharmacol
. 2003 Oct;
140(5):980-6.
PMID: 14517182
In addition to its central role in blood coagulation and hemostasis, human alpha-thrombin is a powerful regulator of inflammatory responses and is known to affect cell-mediated immunity. Interleukin (IL)-12 is...